Timber Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Timber Pharmaceuticals generated cash of -$15,854,921, which is less than the previous year. Cash used in financing activities reached the amount of $8,133,892 last year. Net change in cash is therefore -$7,728,113.
Cash Flow
| 2013 | -7.40K | 0 | 2.92K |
|---|---|---|---|
| 2014 | -6.00M | -263K | 8.37M |
| 2016 | -12.61M | -38K | 15.38M |
| 2018 | -15.58M | -41K | 16.70M |
| 2020 | -1.22M | -384K | 1.68M |
| 2020 | -8.29M | -2.65M | 21.24M |
| 2021 | -9.31M | -17.80K | 15.79M |
| 2022 | -15.85M | -7.08K | 8.13M |
TMBR Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2017 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 16.80M | 10.34M | 57.07K | 0 | 6.50M | 1.30M | 1.30M | 4.64K |
Operating activities | ||||||||
Net income | -19.37M | -10.63M | -15.11M | -3.64M | -16.64M | -15.59M | -7.80M | -52.30K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 326.94K | 272.88K | 116.93K | 0 | 52K | 86K | 25K | 207 |
Stock-based compensation expense | 1.04M | 636.09K | 218.91K | 89.48K | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 1.04M | 636.09K | 218.91K | 89.48K | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | -3K | -6K | -2K | 0 |
Inventories | 0 | 0 | 0 | 0 | 28K | 60K | -138K | 0 |
Accounts payable | 397.44K | 558.3K | -716.52K | 0 | -1.17M | 7K | 257K | 0 |
Cash generated by operating activities | -15.85M | -9.31M | -8.29M | -1.22M | -15.58M | -12.61M | -6.00M | -7.40K |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -7.08K | -17.80K | -750K | 0 | -41K | -38K | -228K | 0 |
Acquisitions Net | 0 | 0 | 340.78K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -7.08K | -17.80K | -2.65M | -384K | -41K | -38K | -263K | 0 |
Financing activities | ||||||||
Common Stock Issued | 7.98M | 15.79M | 17.5M | 0 | 16.04M | 13.31M | 99K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 16.70M | 14.88M | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 8.13M | 15.79M | 21.24M | 1.68M | 16.70M | 15.38M | 8.37M | 2.92K |
Net Change In Cash | -7.72M | 6.45M | 10.29M | 68.48K | 1.07M | 1.42M | 0 | -4.47K |
Cash at end of period | 9.08M | 16.80M | 10.34M | 68.48K | 7.57M | 2.73M | 1.30M | 162 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |